The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Novartis announced the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & ...
read more
Eisai Co. Ltd. and Biogen Inc. announced that the U.S. FDA has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational ...
read more
AbbVie and Teneobio, Inc. announced that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a ...
read more
Heat Biologics, Inc. a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, ...
read more
Eisai Co., Ltd. and Bristol-Myers Squibb Company announced that the companies have entered into an exclusive global strategic collaboration agreement ...
read more
AstraZeneca and MSD's Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, ...
read more
Merck announced that the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based ...
read more
The U.S. FDA approved avapritinib (Ayvakit™, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), including ...
read more
Linnaeus Therapeutics Inc., a privately-held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small ...
read more
FDA approved Mavyret (glecaprevir and pibrentasvir) oral pellets (100mg/40mg) for the treatment of pediatric patients 3 to less than 12 years of age ...
read more
iTeos Therapeutics and GlaxoSmithKline plc agree to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody currently in phase I ...
read more
Avenue Therapeutics Inc, a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, has received a second Complete ...
read more
Novavax Inc announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and...
read more
The U.S. FDA approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at ...
read more
Final results from the head-to-head ELEVATE-RR Phase III trial of AstraZeneca’s Calquence (acalabrutinib) demonstrated non-inferior progression-free ...
read more